Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition

Journal of the European Academy of Dermatology and Venereology

Volumn 19, Issue 3, 2005, Pages 319-322

  Namazi, M R ^a,b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b NONE   (Iran)

Author keywords

Allopurinol; Cannabinoids; Loratadine; Psoriasis; Treatment

Indexed keywords

ALLOPURINOL; ANTIHISTAMINIC AGENT; ANTIPSORIASIS AGENT; CANNABINOID; CYCLIC AMP; CYCLIC GMP; CYCLOSPORIN; CYTOKINE; DRONABINOL; FREE RADICAL; GAMMA INTERFERON; HISTAMINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LEUKOTRIENE B4; LORATADINE; NITRIC OXIDE; PURINE P2X7 RECEPTOR; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; CELL INTERACTION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; DRUG EFFICACY; HUMAN; IMMUNOCOMPETENT CELL; INFLAMMATION; INHIBITION KINETICS; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PSORIASIS; T LYMPHOCYTE; UVEITIS;

ALLOPURINOL; CANNABINOIDS; FREE RADICAL SCAVENGERS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; LORATADINE; PSORIASIS;

EID: 18844458527     PISSN: 09269959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2004.01184.x     Document Type: Article

References (32)

1. Ortonne J-P. Recent development in the understanding of the pathogenesis of psoriasis. Br J Dermatol 1999; 140 (Suppl. 54): S1-S7.
2. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23.
3. Namazi MR. Nicotinamide: a potential addition to the antipsoriatic weaponry. FASEB J 2003; 17(11): 1377-1379.
4. Namazi MR. A complementary note on the Morhenn's hypothesis on the pathomechanism of psoriasis. Immunol Lett 2003; 85: 223.
5. Camisa C. Pathogenesis of psoriasis. In: Camisa C, ed., Handbook of Psoriasis, 1st edn. Blackwell Science Ltd, Oxford, 1998: 49-51.
6. Zemtsov A, Buchino S, McDowell MR. Potential use of leukotriene inhibitors in treatment of psoriasis. Dermatology 2003; 206(2): 179-180.
7. Zemtsov A, Ali-Moncada S. Leukotriene inhibitors maybe effective in treatment of psoriasis. Acta Derm Venereol 2000; 80(5): 389.
8. Black AK, Camp RD, Mallet Al et al. Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J Invest Dermatol 1990; 95: 50-54.
9. Kragballe K, Herlin T. Benoxaprofen improves psoriasis. A double-blind study. Arch Dermatol 1983; 119: 584-552.
10. Degreff H, Dockx P, De Doncker P et al. A double-blind vehicle-controlled study of R 68 151 in psoriasis: a topical 5-lipoxygenase inhibitor. J Am Acad Dermatol 1990; 22: 751-755.
11. Christophers E, Mrowietz U. Psoriasis. In: Freedberg IM, Eisen AZ, Wolff K et al., eds. Fitzpatrick's Dermatology in General Medicine, Vol. 1, 5th edn. McGraw-Hill, New York, 1995: 513.
12. Utas S, Kose K, Yazici C, Akdas A, Kelestimur F. Antioxidant potential of propylthiouracil in patients with psoriasis. Clin Biochem 2002; 38: 241-246.
13. Berdysheve EV. Cannabinoid receptors and the regulation of immune response. Chem Phys Lipids 2000; 108: 169-190.
14. Luo YD, Patel MK, Wielderhold MD, Ou DW. Effects of cannabinoids and cocaine on the mitogen-induced transformations of lymphocytes of human and mouse origin. Int J Immunopharmacol 1992; 14: 49-56.
15. Kelin TW, Kawakami Y, Newton C, Friedman H. Marijuana components suppress induction and cytolytic activity of murine cytolytic T cells in vitro and in vivo. J Toxicol Environ Health 1991; 32: 465-477.
16. 9-tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of post-translational events. J Pharmacol Exp Ther 1993; 267: 1558-1565.
17. Ihenetu K, Molleman A, Parsons M, Whelan C. Pharmacological characterisation of cannabinoid receptors inhibiting interleukin 2 release from human peripheral blood mononuclear cells. Eur J Pharmacol 2003; 467: 207-215.
18. Zurier RB. Prospects for cannabinoids as anti-inflammatory agents. J Cell Biochem 2003; 88: 462-466.
19. Amsellem C, Czarlewski W, Lagarde M, Pacheco Y. Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells. Pulm Pharmacol Ther 1998; 11(4): 245-252.
20. Temple DM, McCluskey M. Loratadine, an anti-histamine, blocks antigen- and ionophore-induced leukotriene release from human lung in vitro. Prostaglandins 1988; 35(4): 349-354.
21. Tasaka K, Kamei C, Akagi M et al. [Effect of loratadine on immediate and delayed type hypersensitivity reactions]. Arzneimitte Forsch 1995; 45 (7): 769-804.
22. Grus FH, Augustin AJ, Loeffler K et al. Allopurinol has immunomodulating activity following topical and systemic application in experimental autoimmune uveitis. Eur J Ophthalmol 2001; 11(3): 252-260.
23. Olah T, Regely K, Mandi Y. The inhibitory effects of allopurinol on the production and cytotoxicity of tumor necrosis factor. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 96-99.
24. Okamoto H, Mizuno K, Hori T. Monocyte-derived multinucleated giant cells and sarcoidosis. J Dermatol Sci 2003; 31: 119-128.
25. Baricordi OR, Ferrari D, Melchiorri L et al. An ATP-activated channel is involved in mitogenic stimulation of human T lymphocytes. Blood 1996; 87(2): 682-690.
26. Virgilio ED. The P2Z purinoceptor: an intriguing role in immunity, inflammation, and cell death. Immunol Today 1995; 16(11): 524-580.
27. Grus FH, Augustin AJ, Loeffler K, et al. Immunological effects of allopurinol in the treatment of experimental autoimmune uveitis (EAU) after onset of the disease. Eur J Ophthalmol 2003; 13(2): 185-191.
28. Foxman EF, Zhang M, Hurst SD, et al. Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1-versus Th2-mediated ocular inflammation. J Immunol 2002; 168(5): 2483-2492.
29. De Kozak Y, Verwaerde C. Cytokines in immunotherapy of experimental uveitis. Int Rev Immunol 2002; 21(2-3): 231-253.
30. Augustin AJ, Loeffler KU, Sekundo W, et al. Effects of systemically applied allopurinol and prednisolone on experimental autoimmume uveitis. Greafes Arch Clin Exp Ophthalmol 1999; 237(6): 508-512.
31. Grus FH, Augustin AJ, Sekundo W, Loeffler K. Immunological effect of systemically administrated allopurinol in experimental autoimmune uveitis. Klin Monatsbl Augenheilkd 2000; 216(3): 165-171.
32. Matuura G, Goto H, Kezuka T, et al. Suppression of experimental uveoretinitis with a combination of cyclosporin and allopurinol. Nippon Ganka Gakkai Zasski 1999; 103: 26-33.